Microbiome Diagnostics Market: By Technology, qPCR/targeted PCR panels, Microarrays/hybridization, and Bioinformatics), By Sample Type, By Application, By Test Purpose, By End User, and Region Forecast 2020-2031
Microbiome Diagnostics Market size was valued at US$ X million in 2024 and is expected to reach US$ X million by 2031, growing at a significant CAGR of X% from 2025-2031. Moreover, in the USA, the Microbiome Diagnostics Market size was valued at US$ xx million in 2024 and is projected to reach US$ xx million by 2031, growing at a CAGR of xx% from 2025-2031. Microbiome diagnostics involves the use of advanced technologies such as next-generation sequencing (NGS), qPCR, mass spectrometry, and bioinformatics to study microbial communities across the human body, including the gut, skin, and oral microbiomes. These tools help identify biomarkers, detect pathogens, assess disease risk, and enable personalized treatment strategies. They play a vital role in disease diagnosis, prognosis, monitoring, and companion diagnostics for gastrointestinal disorders, infections, autoimmune diseases, metabolic conditions, and cancer.
The market is expanding rapidly, driven by the prevalence of chronic diseases, increasing research on microbiome–disease links, and the adoption of precision medicine. Direct-to-consumer wellness and preventive testing kits are also fueling awareness. According to the Human Microbiome Project (NIH), 242 healthy U.S. volunteers provided over 5,000 samples across multiple body sites, leading to the discovery of more than 8 million microbial protein-coding genes far exceeding the ~22,000 human genes. The project also estimated 10,000 microbial species, with 81–99% of genera identified in healthy adults. From 2012–2014, U.S. federal agencies invested US$922 million in microbiome research, while the CDC reports over 2.8 million antimicrobial-resistant infections and 35,000 deaths annually, highlighting the clinical urgency of microbiome diagnostics.
Based on the Technology:
Next-Generation Sequencing (NGS) is a leading microbiome diagnostic technology, enabling simultaneous sequencing of millions of DNA fragments for detailed microbial analysis. The U.S. NIH and National Cancer Institute have funded NGS-based microbiome research and diagnostics, highlighting its critical role in identifying disease-associated microbial signatures and advancing personalized healthcare.
Based on the Sample Type:
The stool sample segment is a key driver in microbiome diagnostics, representing gut microbial health crucial for disease detection. NIST has released a stool reference material to support research, while the U.S. CMS recommends fresh stool samples for accurate gastrointestinal pathogen testing, highlighting its clinical and diagnostic importance.
Based on the Application:
The oncology segment leads microbiome diagnostics, as tumor and gut microbiomes influence cancer development and therapy response. Studies show microbial communities can impact immunotherapy efficacy, while specific microbial signatures serve as potential biomarkers for early detection and prognosis, highlighting the role of microbiome analysis in personalized cancer treatment.
Based on the Test Purpose:
The companion diagnostics segment leads microbiome diagnostics, especially in oncology, by identifying patients likely to benefit from targeted therapies. For example, the U.S. FDA approved FoundationOne CDx tests for BRCA-mutated metastatic prostate cancer, enabling personalized treatment and improving outcomes through microbiome-based biomarker guidance.
Based on the End User:
The Diagnostic Laboratories segment leads the market, providing advanced testing using NGS and qPCR. In India, DBT initiatives have supported over 5,300 biotech start-ups, while ICMR programs promote microbiome research, enhancing laboratory capacity for accurate, personalized diagnostic services
Study Period
2025-2031Base Year
2024CAGR
X%Largest Market
North AmericaFastest Growing Market
Asia-Pacific
The market is rapidly expanding, fueled by the growing burden of chronic diseases such as gastrointestinal disorders, diabetes, obesity, autoimmune conditions, and cancer, which demand earlier and more precise testing. Technological progress in next-generation sequencing (NGS), qPCR, and metagenomics has improved speed and accuracy, while AI and bioinformatics strengthen clinical interpretation. The push toward precision medicine is another major driver, as microbiome-based diagnostics are increasingly used to guide therapy personalization, predict immunotherapy responses, and support drug development.
Government-backed research has underlined the microbiome’s significance. The NIH Human Microbiome Project (HMP) sampled 300 healthy adults (ages 18–40) across five major body sites, collecting over 11,000 specimens. This generated 5,177 taxonomic profiles and more than 3.5 terabases of metagenomic sequence data, uncovering extensive microbial diversity. Researchers estimate the human ecosystem harbors over 10,000 microbial species, with 81–99% of genera in healthy adults identified, and about 8 million unique protein-coding genes compared to only ~22,000 human genes. Globally, more than 444,829 human microbiome samples have been cataloged, with 47% originating from the U.S. Combined with rising direct-to-consumer testing, these factors highlight strong momentum for microbiome diagnostics worldwide.
The market is constrained by several well-documented challenges rooted in standardization, regulatory oversight, and data complexity. For example, reproducibility is a major concern: NIST has released a human gut microbiome reference material to create consistency, and in an inter-lab study involving ~50 labs globally, substantial variation was observed in metagenomic outputs depending on sample collection, DNA extraction, library preparation, and sequencing platform.
Regulatory oversight is likewise uneven; in Europe some microbiome tests are available on the market without a clearly defined regulatory status, while many direct-to-consumer microbiome tests in the U.S. lack strong evidence for analytical or clinical validity. Data and computational analysis also present difficulties: one systematic review of 102 gut microbiome machine-learning studies found that only ~12% of them used a properly independent test set for validating model performance, raising concerns about exaggerated accuracy claims. Combined, these factors high methodological variation, regulatory ambiguity, and potential overfitting or misinterpretation of data poses significant barriers to clinical adoption of microbiome diagnostics.
The market is full of unique opportunity, supported by emerging data and institutional initiatives. For example, the National Institutes of Health is investing in workforce development, a $2.6 million T32 training grant awarded to Penn State will support 5-10 doctoral students annually over the next five years through its BIOMS program. Meanwhile, national survey programs are enriching microbiome data resources: the U.S. NHANES project collected oral microbiome samples from ages 14-69 years in 2009-2012, linking them to detailed health, questionnaire, and biometric data in a representative population. On the research scale, a newly published “Human Microbiome Compendium” has aggregated around 814,916 human gut microbiome samples from 2011 to 2023, highlighting opportunities for large-scale analytics, biomarker discovery, and population-based diagnostic development.
These kinds of large, well-annotated datasets enable better statistical power, discovery of rare microbial signatures, and generalization across geographic and demographic groups. Combined with growing interest in companion diagnostics, preventive consumer health products, AI-driven bioinformatics, and unmet needs in antimicrobial resistance, the ecosystem is primed for innovation and translation into diagnostics with real clinical and public health impact.
The market is witnessing significant growth, driven by technological innovation, rising consumer interest, and supportive regulatory initiatives. One key trend is technological advancement: the cost of genome sequencing has fallen dramatically, making microbiome analysis more affordable and accessible. This enables broader adoption across research institutions, clinical laboratories, and biotech companies, facilitating faster development and commercialization of diagnostic solutions. Consumer interest is another major driver. Companies like Viome, a Washington-based biotech startup, have sold over 500,000 AI-driven at-home testing kits that analyze saliva, stool, and blood samples using RNA sequencing.
These kits provide personalized nutrition and supplement recommendations and are expanding to detect early signs of diseases, including oral and throat cancers, reflecting growing demand for personalized and preventive healthcare. Regulatory support is also strengthening the market. Governments recognize the clinical and therapeutic potential of microbiome research, with the U.S. National Institutes of Health (NIH) actively investing in projects that support microbiome-based diagnostics and therapeutics. Combined, these trends indicate a robust outlook for the market, with continued adoption and innovation expected globally.
The North American region currently leads the market, strengthened by strong healthcare infrastructure and substantial government investments. The U.S. alone accounts for nearly 47% of global human microbiome samples, underscoring its pivotal role in microbiome research and diagnostics. This dominance is further supported by initiatives like the Human Microbiome Project, funded by the National Institutes of Health (NIH), which has significantly advanced our understanding of the human microbiome.
The Asia Pacific market is the fastest growing region. For instance, China's National Natural Science Foundation has been allocating funds to microbiome-related research, reflecting the country's commitment to advancing in this field. Similarly, India's Department of Biotechnology has been actively involved in microbiome research, with the Indian Council of Medical Research (ICMR) receiving approximately 97% of its funding from the Government of India, highlighting the nation's investment in health-related research. Europe holds the second-largest market share, supported by initiatives like the EU’s Horizon 2020, which have fostered collaboration and innovation in microbiome diagnostics.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market CAGR |
X% |
|
By Technology |
|
|
By Sample Type |
|
|
By Application |
|
|
By Test Purpose |
|
|
By End User |
|
|
By Region |
|
The market is experiencing rapid growth, driven by rising chronic disease prevalence, precision medicine adoption, and technological advancements such as next-generation sequencing (NGS), qPCR, mass spectrometry, and bioinformatics. Microbiome diagnostics are increasingly applied in gastrointestinal, metabolic, infectious, and oncological conditions, with companion diagnostics emerging as a critical segment. North America dominates the market, with the U.S. contributing nearly 47% of global microbiome samples and strong federal funding, including US$922 million between 2012–2014, underlining its leadership in research and clinical applications. Asia Pacific is the fastest-growing region, supported by government initiatives in China and India, reflecting increasing investment in microbiome research and healthcare infrastructure.
Key players, including Illumina, Viome, QIAGEN, and Mapmygenome, are expanding through acquisitions, partnerships, and innovative product launches, such as RGCC International’s InVyomma Plus and Metabolon’s multiomics solutions. Diagnostic laboratories remain the leading end-users, leveraging advanced technologies for personalized healthcare. Opportunities abound in large-scale data analytics, AI-driven bioinformatics, preventive health, and companion diagnostics, while standardization, regulatory ambiguity, and computational complexity remain restraints. Overall, the market presents strong potential for clinical and consumer adoption, underpinned by innovation and expanding datasets.
Download Free Sample Report
The microbiome diagnostics market size was valued at US$ X million in 2024 and is projected to grow at a significant CAGR of X% from 2025-2031.
• Rising prevalence of chronic and lifestyle-related diseases
• Advances in sequencing and bioinformatics technologies
• Rising antimicrobial resistance (AMR) threat
• Rising Integration into Precision Medicine • Expansion of Companion Diagnostics • Integration of AI & Bioinformatics
The market report covers the Technology, Sample Type, Application, Test Purpose, End User, and region segments.
DNA Genotek, Illumina, Inc., Quantbiome, Inc., Biome Diagnostics, Genetic Analysis AS, Microba Life Sciences, Viome Life Sciences, Inc., ViennaLab Diagnostics GmbH, Oxford Nanopore Technologies plc, Becton, Dickinson and Company (BD), and among others are the key players in the Microbiome Diagnostics -market.
| 1.Executive Summary |
| 2.Global Microbiome Diagnostics Market Introduction |
| 2.1.Global Microbiome Diagnostics Market - Taxonomy |
| 2.2.Global Microbiome Diagnostics Market - Definitions |
| 2.2.1.Technology |
| 2.2.2.Sample Type |
| 2.2.3.Application |
| 2.2.4.End User |
| 2.2.5.Region |
| 3.Global Microbiome Diagnostics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Microbiome Diagnostics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Microbiome Diagnostics Market By Technology, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Mass spectrometry / proteomics/metabolomics |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Next-Generation Sequencing (NGS) |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. qPCR/targeted PCR panels |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Microarrays/hybridization |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Bioinformatics |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Microbiome Diagnostics Market By Sample Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Stool |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Saliva |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Blood |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Plasma |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Tissue |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Biopsy |
| 6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 6.7. Dermal Swabs |
| 6.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.7.3. Market Opportunity Analysis |
| 7.Global Microbiome Diagnostics Market By Application, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Oncology |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Metabolic Disorders |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Gastrointestinal Disorders |
| 7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Pharmacomicrobiomics |
| 7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Infectious Disease Diagnostics & Pathogen Detection |
| 7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Preventive Screening |
| 7.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.6.3. Market Opportunity Analysis |
| 8.Global Microbiome Diagnostics Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Hospitals |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Specialty Clinics |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Rehabilitation Centers |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Ambulatory Surgery Centers (ASCs) |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Pharmacies & Laboratories |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.Global Microbiome Diagnostics Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Microbiome Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Technology Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Mass spectrometry / proteomics/metabolomics |
| 10.1.2.Next-Generation Sequencing (NGS) |
| 10.1.3.qPCR/targeted PCR panels |
| 10.1.4.Microarrays/hybridization |
| 10.1.5.Bioinformatics |
| 10.2. Sample Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Stool |
| 10.2.2.Saliva |
| 10.2.3.Blood |
| 10.2.4.Plasma |
| 10.2.5.Tissue |
| 10.2.6.Biopsy |
| 10.2.7.Dermal Swabs |
| 10.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Oncology |
| 10.3.2.Metabolic Disorders |
| 10.3.3.Gastrointestinal Disorders |
| 10.3.4.Pharmacomicrobiomics |
| 10.3.5.Infectious Disease Diagnostics & Pathogen Detection |
| 10.3.6.Preventive Screening |
| 10.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospitals |
| 10.4.2.Specialty Clinics |
| 10.4.3.Rehabilitation Centers |
| 10.4.4.Ambulatory Surgery Centers (ASCs) |
| 10.4.5.Pharmacies & Laboratories |
| 10.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Microbiome Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Mass spectrometry / proteomics/metabolomics |
| 11.1.2.Next-Generation Sequencing (NGS) |
| 11.1.3.qPCR/targeted PCR panels |
| 11.1.4.Microarrays/hybridization |
| 11.1.5.Bioinformatics |
| 11.2. Sample Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Stool |
| 11.2.2.Saliva |
| 11.2.3.Blood |
| 11.2.4.Plasma |
| 11.2.5.Tissue |
| 11.2.6.Biopsy |
| 11.2.7.Dermal Swabs |
| 11.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Oncology |
| 11.3.2.Metabolic Disorders |
| 11.3.3.Gastrointestinal Disorders |
| 11.3.4.Pharmacomicrobiomics |
| 11.3.5.Infectious Disease Diagnostics & Pathogen Detection |
| 11.3.6.Preventive Screening |
| 11.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospitals |
| 11.4.2.Specialty Clinics |
| 11.4.3.Rehabilitation Centers |
| 11.4.4.Ambulatory Surgery Centers (ASCs) |
| 11.4.5.Pharmacies & Laboratories |
| 11.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 12.Asia Pacific (APAC) Microbiome Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 12.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Mass spectrometry / proteomics/metabolomics |
| 12.1.2.Next-Generation Sequencing (NGS) |
| 12.1.3.qPCR/targeted PCR panels |
| 12.1.4.Microarrays/hybridization |
| 12.1.5.Bioinformatics |
| 12.2. Sample Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Stool |
| 12.2.2.Saliva |
| 12.2.3.Blood |
| 12.2.4.Plasma |
| 12.2.5.Tissue |
| 12.2.6.Biopsy |
| 12.2.7.Dermal Swabs |
| 12.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Oncology |
| 12.3.2.Metabolic Disorders |
| 12.3.3.Gastrointestinal Disorders |
| 12.3.4.Pharmacomicrobiomics |
| 12.3.5.Infectious Disease Diagnostics & Pathogen Detection |
| 12.3.6.Preventive Screening |
| 12.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospitals |
| 12.4.2.Specialty Clinics |
| 12.4.3.Rehabilitation Centers |
| 12.4.4.Ambulatory Surgery Centers (ASCs) |
| 12.4.5.Pharmacies & Laboratories |
| 12.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Microbiome Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 13.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Mass spectrometry / proteomics/metabolomics |
| 13.1.2.Next-Generation Sequencing (NGS) |
| 13.1.3.qPCR/targeted PCR panels |
| 13.1.4.Microarrays/hybridization |
| 13.1.5.Bioinformatics |
| 13.2. Sample Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Stool |
| 13.2.2.Saliva |
| 13.2.3.Blood |
| 13.2.4.Plasma |
| 13.2.5.Tissue |
| 13.2.6.Biopsy |
| 13.2.7.Dermal Swabs |
| 13.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Oncology |
| 13.3.2.Metabolic Disorders |
| 13.3.3.Gastrointestinal Disorders |
| 13.3.4.Pharmacomicrobiomics |
| 13.3.5.Infectious Disease Diagnostics & Pathogen Detection |
| 13.3.6.Preventive Screening |
| 13.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospitals |
| 13.4.2.Specialty Clinics |
| 13.4.3.Rehabilitation Centers |
| 13.4.4.Ambulatory Surgery Centers (ASCs) |
| 13.4.5.Pharmacies & Laboratories |
| 13.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Microbiome Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 14.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Mass spectrometry / proteomics/metabolomics |
| 14.1.2.Next-Generation Sequencing (NGS) |
| 14.1.3.qPCR/targeted PCR panels |
| 14.1.4.Microarrays/hybridization |
| 14.1.5.Bioinformatics |
| 14.2. Sample Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Stool |
| 14.2.2.Saliva |
| 14.2.3.Blood |
| 14.2.4.Plasma |
| 14.2.5.Tissue |
| 14.2.6.Biopsy |
| 14.2.7.Dermal Swabs |
| 14.3. Application Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Oncology |
| 14.3.2.Metabolic Disorders |
| 14.3.3.Gastrointestinal Disorders |
| 14.3.4.Pharmacomicrobiomics |
| 14.3.5.Infectious Disease Diagnostics & Pathogen Detection |
| 14.3.6.Preventive Screening |
| 14.4. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospitals |
| 14.4.2.Specialty Clinics |
| 14.4.3.Rehabilitation Centers |
| 14.4.4.Ambulatory Surgery Centers (ASCs) |
| 14.4.5.Pharmacies & Laboratories |
| 14.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.DNA Genotek |
| 15.2.2.Illumina, Inc. |
| 15.2.3.Quantbiome, Inc. |
| 15.2.4.Biome Diagnostics |
| 15.2.5.Genetic Analysis AS |
| 15.2.6.Microba Life Sciences |
| 15.2.7.Viome Life Sciences, Inc. |
| 15.2.8.ViennaLab Diagnostics GmbH |
| 15.2.9.Oxford Nanopore Technologies plc |
| 15.2.10.Becton, Dickinson and Company (BD) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
